SYS-CON MEDIA Authors: Elizabeth White, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

CORRECTING and REPLACING MolecularHealth Guides Better Cancer Treatments with Two New Diagnostic Tests

Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

MOLECULARHEALTH GUIDES BETTER CANCER TREATMENTS WITH TWO NEW DIAGNOSTIC TESTS

TreatmentMAP platform combines precision medicine with advanced data analytics to guide patients and physicians to the safest, most effective cancer treatment options

Backed by more than eight years of research and development, MolecularHealth announced today the official launch of TreatmentMAP™, its cancer treatment decision support offering. Based on a proprietary analytics engine, TreatmentMAP leverages the results of next generation sequencing (NGS) genetic tests to identify the optimal, safest treatment options for each individual patient. For the first time, cancer patients and their medical teams will have access to actionable information to guide the selection of targeted cancer treatments, presented in a clear and understandable way. TreatmentMAP became commercially available in Europe and the U.S. in April.

The company has two available versions of its offering:

  • TreatmentMAP Targeted Panel is the largest gene panel commercially available today, with over 500 genes that cover several thousand variants and have been determined to have the most clinical impact in cancer, and are therefore most likely to make a difference in treatment outcome.
  • TreatmentMAP Whole Exome, the first commercially available whole exome analysis for cancer, taking a comprehensive look at a patient’s genetic profile by examining the genes of both the tumor and germline.

Both testing options incorporate MolecularHealth’s SafetyMAP™, a proprietary identification of drug target safety or resistance effects, using the FDA’s Adverse Event Reporting Systems (AERS) as an input for analysis. Through MolecularHealth’s five-year research collaboration agreement with the FDA, MolecularHealth incorporates key data from AERS into SafetyMAP, providing the first drug safety analysis that combines adverse event information with molecular knowledge about drug activity within a patient. This ensures that treatment options will not only be effective, but won’t have unintended negative consequences for patients.

“I believe that the future of medicine lies in our ability to interpret seemingly disparate information,” said Lloyd Everson, M.D., co-CEO of MolecularHealth. “With the technology now at our disposal, there are mountains of data constantly being churned out of labs and clinical trials – but until recently, it was an unwieldy task to do anything productive with that information. TreatmentMAP allows us to pull in all of that data and make it truly usable.”

TreatmentMAP tests can be ordered in the United States and in Europe. In the U.S., a patient’s oncologist or pathologist sends a tumor sample to MolecularHealth’s CLIA-certified NGS lab in The Woodlands, Texas. Once the sample is sequenced, data on the tumor’s DNA, along with additional medical information on the patient, is fed into the company’s automated analytics platform. This platform cross-references patient-specific data with the latest peer-reviewed evidence, clinical trials, and other sources. A simple-to-understand report is delivered to the patient’s medical team, highlighting the treatment options that are most likely to be both effective and safe.

“We are still trying to understand cancer, and as an oncologist I have observed that the most effective cancer therapies are those that precisely target the unique biology of an individual patient's tumor,” said Joyce O’Shaughnessy, M.D., co-chair of breast cancer research at US Oncology and Baylor-Sammons Cancer Center. “TreatmentMAP offers new insights into the molecular drivers of a tumor, leading to expanded therapeutic options and greater chance for therapy response.”

“As a pathologist, I’m happy to have a company joining the molecular diagnostic space that’s more pathologist-friendly than some of the competition in this field,” said Thomas Wheeler, M.D., chairman of the Department of Pathology & Immunology at Baylor College of Medicine. “The market can only benefit from having more options to meet the needs of individual patients, and from what I’ve seen, MolecularHealth’s reports are not only more robust, but focus on the elements that are most important when determining a treatment path for a patient.”

Drs. O’Shaughnessy and Wheeler are members of the MolecularHealth advisory board.

For more information on TreatmentMAP and how to order a test, please visit MolecularHealth’s website.

ABOUT MOLECULARHEALTH

MolecularHealth is a leading biomedical company transforming molecular data into actionable clinical information for the most efficient and safest cancer treatment options for each individual cancer patient. By using advanced proprietary tumor analysis and interpretation to match patient-specific genetic and molecular test findings to the current state of the world’s biomedical knowledge about cancer, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world’s leading healthcare and information technology companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, and SAP AG. The company is headquartered in Heidelberg, Germany. U.S. headquarters, including a CLIA-certified NGS lab, are located in The Woodlands, Texas. The company also has offices in Boston, Mass.

Website: www.molecularhealth.com
Twitter: www.twitter.com/molecularhealth
LinkedIn: www.linkedin.com/company/molecularhealth
YouTube: www.youtube.com/user/MolecularHealthInc

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.